^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Glioblastoma
    Drug:Visudyne (verteporfin) (Reactive oxygen species stimulant, Photosensitizer)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

    Excerpt:
    ...- Eligible participants have tumors that show mutant or amplified EGFR....
    Trial ID:
    NCT04590664
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    YAP/TAZ transcriptional co-activators create therapeutic vulnerability to verteporfin in EGFR mutant glioblastoma

    Published date:
    11/10/2020
    Excerpt:
    ...the benzoporphyrin derivative verteporfin, a disruptor of YAP/TAZ-TEAD mediated transcription, preferentially induced apoptosis of cultured patient-derived EGFR-amplified/mutant GBM cells, suppressed expression of YAP/TAZ transcriptional targets, including EGFR, and conferred significant survival benefit in an orthotopic xenograft GBM model....Together, our data suggest that verteporfin is a promising therapeutic agent for EGFR amplified and mutant GBM.
    DOI:
    10.1158/1078-0432.CCR-20-0018